VIRO 2026 – Global Voices in Renal Oncology
Highlights From VIRO 2026 – Global Voices in Renal Oncology, Day 1
Discussions Around the DeLLphi-305 Trial
Sevabertinib Moves Into First-Line HER2-Mutant NSCLC With FDA Accelerated Approval
MOB-RT Supports Moderate Hypofractionated Pelvic Radiotherapy in High-Risk Prostate Cancer
Benjamin L. Ebert: A Major Step Forward for Personalized Cancer Vaccines
Hodgkin Lymphoma in 2026: What the New EHA Guidelines Recommend
FDA Expands Accelerated Approval of Sevabertinib for HER2-Mutant Non-small Cell Lung Cancer
